Insomnia and its association with quality of life in women with ovarian cancer

Ross, Tanya; deFazio, Anna; Friedlander, Michael; Grant, Peter; Nagle, Christina M.; Williams, Merran; Webb, Penelope M.; Beesley, Vanessa L.

doi:10.1016/j.ygyno.2020.06.500

Cited by 20 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In women with OC, insomnia symptoms tend to persist for years after OC diagnosis. Insomnia symptoms are considered among the risk factors for persistent and troublesome physical and psychological symptoms (Beesley et al, 2020; van Walree et al, 2019; Webber et al, 2019), for a higher risk of invasive serous OC (Liang et al, 2020), poorer recovery from depression and anxiety (Irwin, 2013), and for a greater severity of other cancer‐related symptoms, especially daytime fatigue in OC survivors (Joly et al, 2019), with a negative impact on wellbeing and quality of life (de Arruda et al, 2019; Beesley et al, 2020; Ross et al, 2020; Table 1). No studies have been conducted on insomnia treatment in OC.…”

Section: Resultsmentioning

confidence: 99%

“…invasive serous OC (Liang et al, 2020), poorer recovery from depression and anxiety (Irwin, 2013), and for a greater severity of other cancer-related symptoms, especially daytime fatigue in OC survivors , with a negative impact on wellbeing and quality of life (de Arruda et al, 2019;Beesley et al, 2020;Ross et al, 2020; Table 1). No studies have been conducted on insomnia treatment in OC.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

“…Although sleep disorders can occur singly or in combination and can include different types of sleep disturbances, insomnia symptoms are the most frequent sleep disorder in the oncological population, affecting 30%–50% of patients with OC (Ancoli‐Israel, 2015; Berger, Matthews, & Kenkel, 2017; Howell et al, 2014; Matthews, Carter, Page, Dean, & Berger, 2018; Otte et al, 2015). In patients with OC, insomnia symptoms tend to persist for years after OC, being related to symptoms persistency (Beesley et al, 2013, 2020), higher risk of invasive serous OC (Liang et al, 2020), poorer recovery from depression and anxiety (Irwin, 2013), and greater severity of other cancer‐related symptoms, in particular daytime fatigue in survivors (Joly et al, 2019), affecting wellbeing and quality of life (Beesley et al, 2020; Ross et al, 2020). Insomnia in OC becomes a domain of measuring quality of life based on patient‐reported outcomes (Donovan et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity

Palagini

Massa

Folesani

et al. 2021

Journal of Sleep Research

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynaecological cancer deaths and the seventh most commonly diagnosed cancer among women worldwide, so that, as it is related to substantial and increasing disease burden, the management of ovarian cancer survivors should be a priority. Such issues involve prevention and management of emotional distress, anxiety/depressive symptoms, and maintenance of quality of life from initial diagnosis to post‐treatment. Within this framework, sleep disturbances, in particular insomnia, are emerging as modifiable determinants of mental health, also contributing to substantial morbidity among cancer, including ovarian cancer. To this aim we conducted a systematic review according to PRISMA guidelines on prevalence and management of insomnia and circadian sleep disorders in ovarian cancer, while selecting 22 papers. Insomnia was evaluated in ovarian cancer and, while circadian sleep disturbances were poorly assessed in ovarian cancer, insomnia increased from 14% to 60% of patients. Insomnia was associated with cancer‐related comorbid conditions such as emotional distress, anxiety/depressive symptoms and low quality of life. Despite this evidence, no studies have been conducted about insomnia treatment in ovarian cancer. The burden of insomnia and circadian sleep disorders in patients with ovarian cancer still needs to be addressed, and requires a call to action for the evaluation and management of these potential modifiable factors that might contribute to ovarian cancer morbidity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity

Palagini

Massa

Folesani

et al. 2021

Journal of Sleep Research

View full text Add to dashboard Cite

show abstract

“…In contrast, patients with ovarian cancer often report a higher sleep disorder rate compared with the general population before they undergo surgery, with some studies showing as many as two thirds of patients with ovarian cancer having poor sleep quality, as measured by a PSQI > 5, that can persist over a year after diagnosis 5 33 35. The highest prevalence of this insomnia occurs at 3 months after diagnosis 41…”

Section: Sleep In Gynecological Oncology Patientsmentioning

confidence: 99%

Sleep and gynecological cancer outcomes: opportunities to improve quality of life and survival

Zhao

Grubbs

Barber

2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Sleep is important for immune function, metabolic function and physical repair. Sleep is more commonly disrupted in women compared with men and is disrupted by surgery, chemotherapy, and cancer itself, making gynecological oncology patients at higher risk of insomnia and sleep disruption. Insomnia and sleep disruption are linked to increased pain, poorer quality of life, depression, and anxiety which can all negatively affect patient outcomes. A number of environmental, behavioral, and pharmacological interventions have been investigated to improve patient sleep and aid in the recovery process. It is vital to understand and address patient sleep quality in order to give patients the highest quality care and improve outcomes.

show abstract

“…Sleep difficulties, particularly symptoms of insomnia and circadian disruption, are common among gynecologic cancer survivors (Westin et al, 2016;Campbell et al, 2019;Palagini et al, 2021), with recent research demonstrating an estimated prevalence greater than 80% (Pozzar et al, 2021). Sleep disturbance has also been associated with poorer health-related quality of life (HRQOL) and higher symptom burden in this population (Ross et al, 2020). Difficulty sleeping is often treated with Cognitive Behavioral Therapy for Insomnia (CBT-I), the gold-standard treatment for insomnia, including among those with comorbid conditions (Schutte-Rodin et al, 2008;Qaseem et al, 2016;van Straten et al, 2017).…”

Section: Introduction Sleep Disturbance In Cancer Survivorshipmentioning

confidence: 99%

Optimizing a Behavioral Sleep Intervention for Gynecologic Cancer Survivors: Study Design and Protocol

et al. 2022

View full text Add to dashboard Cite

Sleep difficulties, particularly symptoms of insomnia and circadian disruption, are among the primary complaints of gynecologic cancer survivors before, during, and after treatment. Moreover, difficulty sleeping has been linked to poorer health-related quality of life and elevated symptom burden in this population. Although leading behavioral sleep interventions have demonstrated efficacy among cancer survivors, up to 50% of survivors are non-adherent to these treatments, likely because these interventions require labor-intensive behavior and lifestyle changes. Therefore, there is a need for more effective and acceptable approaches to diminish sleep disturbance among cancer survivors. This manuscript describes the methodology of a two-part study guided by the Multiphase Optimization Strategy (MOST) framework to identify a streamlined behavioral sleep intervention for gynecologic cancer survivors. Three candidate intervention components previously shown to decrease sleep disturbance will be evaluated, including sleep restriction, stimulus control, and systematic bright light exposure. Participants will be adult women with a history of non-metastatic gynecologic cancer who have completed primary treatment and who report current poor sleep quality. Fifteen participants will be recruited for Part 1 of the study, which will utilize qualitative methods to identify barriers to and facilitators of intervention adherence. Results will inform changes to the delivery of the candidate intervention components to promote adherence in Part 2, where 80 participants will be recruited and randomized to one of eight conditions reflecting every possible combination of the three candidate intervention components in a full factorial design. Participants will complete assessments at baseline, post-intervention, and 3-months post-intervention. Part 2 results will identify the combination of candidate intervention components that yields the most efficacious yet efficient 6-week intervention for diminishing sleep disturbance. This is the first known study to apply the MOST framework to optimize a behavioral sleep intervention and will yield a resource-efficient treatment to diminish sleep disturbance, improve health-related quality of life, and decrease symptom burden among gynecologic cancer survivors. ClinicalTrials.gov Identifier: NCT05044975.

show abstract

Insomnia and its association with quality of life in women with ovarian cancer

Cited by 20 publications

References 27 publications

Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity

Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity

Sleep and gynecological cancer outcomes: opportunities to improve quality of life and survival

Optimizing a Behavioral Sleep Intervention for Gynecologic Cancer Survivors: Study Design and Protocol

Contact Info

Product

Resources

About